Posted On: 08/21/2015 1:08:44 PM
Post# of 72443
I'm looking for a gap VERY similar drano. Love to be in one that does it. CTIX has that potential imo. Kevetrin data from Dana Farber would have the power, and it's right around the corner.
Quote:
What NVS paid for a Phase 2 MS drug is 5 times our market cap.
FIVE times. And with royalties and another 200 million of progress payments.
We're about to enter Phase 3 with Brilacidin.
Shorts should be very scared. I hope they are all massively short when a deal is announced.
Remember, one day DNDN closed at 7. The next day it opened at 21.
It could happen for us.
(0)
(0)Scroll down for more posts ▼
